This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST

This study is currently recruiting participants.
See Contacts and Locations
Verified March 2017 by Øyvind Sverre Bruland, Oslo University Hospital
Information provided by (Responsible Party):
Øyvind Sverre Bruland, Oslo University Hospital Identifier:
First received: October 4, 2016
Last updated: March 15, 2017
Last verified: March 2017
The trial "The stop-GIST trial" is an Oslo University Hospital sponsored, prospective, open-label, 1-group, multicenter phase II trial evaluating discontinuation of imatinib in highly selected patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no detectable overt GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or radiofrequency ablation (RFA) of the metastases.

Condition Intervention Phase
Gastrointestinal Stromal Tumor Other: Discontinuation of imatinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Discontinuation of Imatinib in Patients With Oligo-metastatic Gastrointestinal Stromal Tumor That Has Become Radiologically Undetectable With Treatment

Resource links provided by NLM:

Further study details as provided by Øyvind Sverre Bruland, Oslo University Hospital:

Primary Outcome Measures:
  • Progression free survival (PFS) [ Time Frame: 3 years ]
    Three-year progression-free survival (PFS) after discontinuation of imatinib.

Secondary Outcome Measures:
  • Overall survival (OS) [ Time Frame: 3 years ]
    Overall survival will be measured from the date of discontinuation of imatinib to the date of death resulting from any cause.

  • Quality of Life (QoL) [ Time Frame: 3 years ]

Estimated Enrollment: 31
Study Start Date: January 2017
Estimated Study Completion Date: November 2022
Estimated Primary Completion Date: November 2022 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Discontinuation of imatinib
Patients treated with imatinib longer than 5 years for oligo-metastatic GIST (≤ 3 metastases) and who have no longer detectable GIST lesions on CT/MRI imaging following complete surgical resection (R0/R1-resection) or RFA of the metastases are assigned to discontinue imatinib.
Other: Discontinuation of imatinib

Detailed Description:
Patients with metastatic GIST are currently recommended to have life-long treatment with tyrosine kinase inhibitors (TKI). The standard first-line treatment is imatinib, which is switched to other drugs at progression or if the patient does not tolerate imatinib. The prevailing hypothesis is that imatinib and other TKIs fail to completely eradicate metastatic GIST and that progression is inevitable if imatinib treatment is discontinued. However, the SSGXVIII/AIO trial found that 3 years of adjuvant imatinib yielded both superior RFS and OS rates compared to 1 year of adjuvant imatinib, which finding does not exclude the hypothesis that sufficiently long administration of imatinib might sometimes eradicate subclinical GIST. Furthermore, a few retrospective studies have reported favorable survival outcomes with surgery of residual disease in metastatic GIST in patients responding to imatinib, and a subset (approximately 20%) of patients with advanced GIST do not progress within the first 10 years on imatinib. Imatinib treatment comes with potential side-effects and, as of now, considerable costs to the society. Therefore, discontinuation of imatinib in highly selected patients, i.e. those who have received imatinib for longer than 5 years and who have undergone metastasectomy of all macroscopic oligometastatic disease, needs to be explored as a novel treatment strategy. Discontinuation might lead to detection of durable complete remissions without imatinib or even cure.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Age ≥ 18.
  2. Morphological and immunohistochemical documentation of GIST (immunostaining for KIT/ (CD117) and/or DOG-1 (anoctamin-1)) must be positive on a tumour sample. Patients with demonstrated mutation in KIT or PDGFRA may be entered to the study despite negative immunostaining for KIT and DOG-1 provided that tumour histology is compatible with GIST.
  3. Confirmed metastatic disease by radiology, histology, or both in history.
  4. >5.0 years of treatment with imatinib for metastatic disease when the breaks in imatinib administration are taken into account.
  5. No more than 3 detectable metastases in the liver and/or in the abdomen on imaging of the abdomen and the pelvis or at surgery during the course of the disease.
  6. Macroscopically complete resection of all metastases (either R0 or R1 surgery). Patients who have microscopically infiltrated margins (or suspected microscopical infiltration, R1) are eligible to enter the study. Radiofrequency ablation (RFA) of liver metastases in place of surgery is also allowed. Patients whose oligometastatic disease had disappeared completely so that no remaining target lesion for surgery or RFA can be identified (including absence of residual cyst-like lesions) are allowed to enter the study.
  7. Eastern Co-operative Oncology Group (ECOG) performance status ≤ 2.
  8. Patient has provided a written, voluntary informed consent prior to study entry and any study-specific procedures.

Exclusion Criteria:

  1. Patients with metastases outside of the abdomen (e.g. in the bones or lungs).
  2. Not willing to donate tumor tissue and/or blood samples for the molecular studies that aim at predicting of GIST recurrence.
  3. Presence of a mutation in SDH, or other evidence for SDH deficiency.
  4. Presence of neurofibromatosis-1.
  5. R2 resection of the primary tumour or metastasis.
  6. Patient with inability to grant reliable informed consent.
  7. Inability to comply with the scheduled follow-up.
  8. Progressive disease during imatinib or other systemic treatments for GIST, before or after surgery/RFA of the metastases.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02924714

Contact: Øyvind S Bruland, MD PhD 22934767 ext 47
Contact: Ivar Hompland, MD 22931236 ext 47

Oslo University Hospital Recruiting
Oslo, Norway
Contact: Øyvind S Bruland         
Principal Investigator: Øyvind S Bruland         
Sponsors and Collaborators
Oslo University Hospital
Study Director: Heikki Joensuu, MD PhD Comprehensive Cancer Center Helsinki
Principal Investigator: Øyvind S Bruland, MD PhD Oslo University Hospital
  More Information

Responsible Party: Øyvind Sverre Bruland, Professor in clinical oncology, Oslo University Hospital Identifier: NCT02924714     History of Changes
Other Study ID Numbers: SSG XXV: Stop-GIST
Study First Received: October 4, 2016
Last Updated: March 15, 2017

Keywords provided by Øyvind Sverre Bruland, Oslo University Hospital:

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Gastrointestinal Diseases
Digestive System Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 20, 2017